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and Meta-Analysis
Eduardo Villamor-Martinez 1†, Mohammed A. Kilani 1†, Pieter L. Degraeuwe 1,
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It is generally accepted that intrauterine growth restriction (IUGR) increases morbidity
and mortality among very preterm neonates. However, evidence is hampered by the
widespread practice of using the terms small for gestational age (SGA) and IUGR as
synonyms. We conducted a systematic review of studies reporting on the association
between IUGR/SGA and patent ductus arteriosus (PDA). PubMed/MEDLINE and
EMBASE databases were searched. Of 993 studies reviewed, 47 (50,790 infants)
were included. Studies were combined using a random effects model and sources
of heterogeneity were determined by subgroup and meta-regression analyses.
Meta-analysis of all included studies showed a significantly reduced risk of PDA in the
SGA/IUGR group with an odds ratio (OR) of 0.82, and a 95% confidence interval (CI)
of 0.70 to 0.96 (p = 0.015). Of the 47 studies, only 7 used a definition for growth
restriction that went beyond birth weight (BW) for gestational age (GA). When pooled,
meta-analysis could not demonstrate a significant effect size (OR 1.31, 95% CI 0.75
to 2.27, p = 0.343). Moreover, the significantly reduced risk of PDA was found in the
25 studies defining SGA as BW <10th percentile (OR 0.81, 95% CI 0.66 to 0.98,
p = 0.032), but not in the 6 studies defining SGA as BW <3rd (OR 1.09, 95% CI
0.70 to 1.71, p = 0.694), or in the 27 studies using a more refined definition of PDA
(i.e., hemodynamically significant PDA or PDA requiring treatment, OR 0.87, 95% CI
0.72 to 1.04, p = 0.133). In addition, we found that GA was significantly higher in the
SGA/IUGR group (18 studies, mean difference 0.63 weeks, 95% CI 0.24 to 1.03, p
= 0.002). Meta-regression analysis confirmed the correlation between this difference
in GA and PDA risk. In summary, we observed marked heterogeneity across studies
in the definition of growth restriction and PDA, and we found differences between the
control and growth-restricted groups in relevant baseline characteristics, such as GA.
Therefore, our meta-analysis could not provide conclusive evidence on the association
between growth restriction and PDA.
Keywords: small for gestational age, growth restriction, patent ductus arteriosus, very preterm infant, meta-
analysis, meta-regression
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INTRODUCTION
The ductus arteriosus (DA) of very preterm infants is less likely
to close spontaneously as part of the transition to extrauterine life
and, consequently, the incidence of patent DA (PDA) is inversely
related to gestational age (GA) at birth (1–4). Intrauterine or
fetal growth restriction (IUGR/FGR) is commonly recognized
as an additional major risk factor for mortality and morbidity
in very preterm infants (5–11). One of the conditions that
IUGR has been associated with is PDA (12–14), but the
evidence supporting this association is scarce and has not been
systematically reviewed. Some studies even suggest that IUGR
may protect against PDA (15–18).
A common problem of studies assessing the potential
association of growth restriction with adverse neonatal outcomes
is that they do not differentiate between small for gestational
age (SGA) and IUGR, even though the two terms are not
synonymous (7–10). SGA is a statistical definition based on birth
weight (BW), with the 10th percentile as the most commonly
used threshold. The term SGA differs from IUGR principally
because it also encompasses constitutionally small but healthy
infants at lower risk of abnormal perinatal outcome. On the
other hand, growth restricted infants who have a BW above
the 10th percentile may be falsely classified as normally grown
(6–10).
The most common cause of IUGR is placental insufficiency
leading to fetal hypoxia and undernutrition (19). Whether the
normal development of the DA is affected by these pathological
conditions remains largely unknown. Experimental animal
studies showed that reactivity of DA is impaired by exposure to
chronic fetal hypoxia (20, 21). King et al. showed histological
evidence of accelerated DA maturation in very preterm infants
exposed to chronic intrauterine stress, leading to the hypothesis
that this may have resulted in earlier postnatal DA closure
(22). In contrast, Ibara et al. described alterations in the DA of
preterm infants with IUGR (23). These include fragmentation,
coagulation and necrosis of the internal elastic lamina, as well
as hemorrhage with necrosis and loosening of elastic fibers
and muscles in the tunica media (23). These ductal changes
may explain why hemodynamically significant PDA (hsPDA)
has been reported to occur more frequently and at an earlier
postnatal age in very preterm infants with IUGR (12, 13).
We aimed to carry out a systematic review of observational
studies reporting on the association between IUGR/SGA and
PDA. We paid particular attention to how the criteria used
to define growth restriction and PDA affected the potential
association between the two conditions. We also analyzed the
role of potential confounders, such as GA and rate of respiratory
distress syndrome (RDS).
METHODS
The methodology of this study is based on that of earlier
studies of our group on chorioamnionitis and various
morbidities (24–26) and PDA and platelet counts (27).
The study is reported according to the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines (28). The PRISMA checklist is included in the
Supplementary Material. We developed a protocol a priori
defining the objectives, methods, inclusion criteria and approach
to assessing study quality.
Data Sources and Search Strategy
We performed a comprehensive systematic literature search
using the PubMed/MEDLINE and EMBASE databases. The first
search was performed on October 1st, 2016. Automated alerts
were used during the elaboration of the review to maintain
the search up to date. The search strategy was as follows for
PubMED: (PDA OR ductus arteriosus) AND (preterm OR
premature) AND (IUGR OR growth restriction OR growth
retardation OR restricted growth OR fetal growth OR fetus
growth OR reduced growth OR prenatal growth OR placental
dysfunction OR placental insufficiency OR chronic hypoxia OR
chronic hypoxemia OR small for gestational age OR small for
date OR SGA). We used a similar strategy for EMBASE. There
were no language preferences set. Reference lists of relevant
primary and review articles were searched for additional studies.
The “cited by” function in Web of Science and Google Scholar
was also used to expand the search parameters and ensure that
all relevant studies were found.
Study Selection
We included studies which reported on a growth restricted (SGA,
IUGR, FGR) group and a comparison group, studied (very and
extremely) preterm infants, and reported primary data that could
be used to measure the association of SGA/IUGR and PDA. To
assess relevance, two reviewers (MAK, PLD) screened the results
of the searches and applied inclusion criteria using a structured
form. Disagreements were resolved through discussion or in
consultation with a third reviewer (EV).
Data Extraction
A predetermined designed data extraction form was used. Data
was extracted from relevant studies by two investigators (MAK,
PLD). Accuracy and completeness of the data extraction was then
assessed by two other investigators (EVM, EV). Data extracted
from each study included citation information, country where
research was conducted, language of publication, study design,
objectives, inclusion/exclusion criteria, definitions of SGA/IUGR
and PDA, patient characteristics [including GA and birth weight
(BW)], and results (including raw numbers and adjusted analyses
on SGA/IUGR and PDA where available). When studies assessed
PDA at several time points, we used the PDA incidence at the last
time of assessment for data analysis.
Quality Assessment
We assessed study quality using the Newcastle-Ottawa Scale
for assessing the quality of non-randomized studies in meta-
analyses. This scale allocates points for quality in the domains
of selection (0–4 points), comparability (0–2 points), and
outcome/exposure (0–3 points), for a total of 0–9 points. The
process was carried out by two reviewers independently (EVM
and EV). Discrepancies were resolved through discussion.
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Statistical Analysis
Studies were pooled and analyzed using COMPREHENSIVE
META-ANALYSIS V 3.0 software (CMA, RRID:SCR_012779,
Biostat Inc., Englewood, NJ, USA). For dichotomous outcomes,
the odds ratio (OR) with 95% confidence interval (CI) was
calculated from the data provided in the studies. For continuous
outcomes, the mean difference (MD) with 95% CI was calculated.
When studies reported continuous variables as median and range
or interquartile range, the mean and standard deviation were
estimated using the method of Wan et al. (29).
Summary statistics were calculated with a random-effects
model because of anticipated heterogeneity. This model accounts
for variability between and within studies. Subgroup analyses
were used to analyze sources of heterogeneity. They were based
on the mixed-effects model (30). In this model, a random effect
model is used to pool studies within each subgroup and a fixed
effect model is used to combine the subgroups and generate the
summary effect. We assumed a common among-study variance
component (tau-squared) across subgroups.
We determined a priori that we would create subgroups for
SGA/IUGR definition, PDA definition, and for studies which
only included extremely preterm infants (GA <28 weeks).
We also decided to carry out meta-analyses of the following
covariates in the SGA and control groups: GA, BW, rate of
RDS, and rate of antenatal corticosteroids (ACS). Statistical
heterogeneity was assessed using Cochran’s Q statistic and I2
statistic, which is a derivative from Q and demonstrates the
chance of total variation resulting from heterogeneity beyond
chance (30). A univariate random-effects meta-regression
(method of moments) was used to investigate the role of GA,
rate of RDS, and rate of ACS in explaining differences in effect
sizes among studies (30). Meta-regression was also used to
compare subgroups. Publication bias was evaluated by using
Egger’s regression test and through visual inspection of funnel
plots. We considered a probability value of less than 0.05 (0.10
for heterogeneity) as statistically significant.
RESULTS
Included Studies
We identified 993 potentially relevant studies from which 47
(50,790 patients, 7,860 SGA/IUGR cases, 17,300 PDA cases) met
the inclusion criteria (5, 12, 13, 15–18, 31–70). The PRISMA
search diagram is depicted in Supplementary Figure 1 and
the main characteristics of the included studies are shown in
Supplementary Table 1.
While all studies provided data to measure the association
between SGA/IUGR and PDA, only 3 of the studies were
primarily designed to assess this association (13, 32, 69).
Twenty-three studies reported on risk factors for PDA,
and IUGR/SGA was one of the risk factors considered
(Supplementary Table 1). Twenty-one studies examined
the outcomes of IUGR/SGA infants, and PDA was one of the
outcomes studied (Supplementary Table 1).
Forty studies defined growth restriction based on BW below
a determined percentile for GA (Figure 1). From these studies,
25 used the 10th percentile, 2 studies used the 5th percentile, and
6 studies used the 3rd percentile (or −2 standard deviations)
(Figure 1). Seven studies did not specify which criteria or
percentile was used to define growth restriction (Figure 1).
One study used an ultrasound estimated fetal weight chart (48).
Six studies used customized BW charts, which adjusted for
factors such as sex, ethnicity, socioeconomic status, or parity
(15, 17, 35, 50, 57, 63). Thirty-three studies used population-
based BW charts (Supplementary Table 1). Eighteen of these 33
studies used sex-specific charts, and 15 used charts that did not
differentiate by sex.
Seven studies used a definition of growth restriction that went
beyond the use of BW for GA and that included fetal assessment.
Of these, 2 studies used a definition of deviation of fetal growth
(13, 61), and in 5 studies fetal growth restriction was defined
through the presence of an abnormal Doppler result (absent
end-diastolic flow in the umbilical artery) (12, 41, 44, 46, 47).
The assessment of PDA was based solely on clinical criteria in
one study (31), whereas the other studies used heart ultrasound
or ultrasound combined with clinical criteria. Thirteen studies
defined PDA as significant or hemodynamically significant
PDA, and 14 studies defined PDA based on the necessity of
treatment (Figure 2 and Supplementary Table 1). Two studies
defined all ductal shunts, including the small ones, as PDA
(Supplementary Table 1). In 7 studies a definition or definition
criteria for PDA was not specified (Supplementary Table 1).
Quality Assessment
The quality of each study was assessed using the Newcastle-
Ottawa Scale and is summarized in Supplementary Table 2.
Twelve studies scored 6 points (out of 9), 24 studies scored 7
points, and 11 studies scored 8 points. Studies were downgraded
in quality mostly for not adjusting/matching for confounders (k
= 44), for not clearly defining SGA/IUGR (k = 7), and for not
clearly defining PDA (k= 9).
Meta-Analysis Results
As shown in Figure 1, meta-analysis of all 47 included
studies found a significant negative association between
being SGA/IUGR and developing PDA (OR 0.82, 95% CI
0.70–0.96). Neither visual inspection of the funnel plot
(Supplementary Figure 2) nor Egger’s regression test (p= 0.079)
suggested publication bias. The association between growth
restriction and PDA remained negative and significant when
only evaluating studies which defined SGA through BW for GA
(40 studies, OR 0.79, 95% CI 0.67–0.93). We further divided
this group of studies according to the cut-off percentile. In the
meta-analyses of studies using the 10th percentile (25 studies,
OR 0.81, 95% CI 0.66–0.98) and studies where the percentile
was not reported (7 studies, OR 0.55, 95% CI 0.36–0.86) the
significant negative association between SGA and PDA was
maintained (Figure 1). In contrast, meta-analyses of studies
using the 5th percentile (2 studies, OR 0.63, 95% CI 0.26–1.52),
and meta-analysis of studies using the 3rd percentile (6 studies,
OR 1.09, 95% CI 0.70–1.71) could not demonstrate a significant
association between being SGA and PDA (Figure 1). When
examining the subgroup of studies that used a definition for
IUGR that went beyond BW for GA (i.e., presence of abnormal
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FIGURE 1 | Meta-analysis of the association of small for gestational age (SGA)/intrauterine growth restriction (IUGR) and patent ductus arteriosus (PDA). CI:
confidence interval; BW: birth weight; <P10: BW lower than 10th percentile; <P5: BW lower than 5th percentile; <P3: BW lower than 3rd percentile.
Doppler or assessment of fetal growth), meta-analysis could not
find a significant association between IUGR and PDA (7 studies,
OR 1.31, 95% CI 0.75–2.27, Figure 1). When further subdividing
by definition of IUGR, the association remained non-significant
for the 5 studies using the abnormal Doppler criteria (OR 1.67,
95% CI 0.71–3.96) and for the 2 studies assessing fetal growth
(OR 0.89, 95% CI 0.24–3.38).
To evaluate the role of PDA definition, we performed a
further meta-analysis including only studies which defined PDA
as hemodynamically significant or PDA requiring treatment.
This meta-analysis could not find a significant association
between SGA/IUGR and PDA in either subgroup (hsPDA: OR
0.92, 95% CI 0.71–1.20; PDA requiring treatment: OR 0.82, 95%
CI 0.64–1.06), or when combining the two subgroups (OR 0.87,
95% CI 0.72–1.04, Figure 2).
To explore sources of heterogeneity, we carried out several
additional meta-analyses of covariates, subgroup analyses and
meta-regression analyses. Firstly, we examined the role of GA as
a confounder in the association between SGA/IUGR and PDA.
Six case-control and 13 cohort studies reported data on GA in
the SGA/IUGR and the control group. Meta-analysis found that
infants in the SGA/IUGR group were born significantly later
(18 studies, MD 0.63 weeks, 95% CI 0.24 to 1.03, Figure 3)
than infants in the control group. Although this effect was more
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FIGURE 2 | Subgroup meta-analysis of studies using a definition of significant patent ductus arteriosus (PDA) (i.e., hemodynamically significant PDA or PDA requiring
treatment). Analysis on the association of growth restriction and PDA. Req: requiring; CI: confidence interval; SGA: small for gestational age; IUGR: intrauterine growth
restriction; hsPDA: hemodynamically significant PDA.
pronounced in cohort studies, it was also found in some case-
control studies (Figure 3). The difference in GA between the SGA
and the control group was particularly marked in the 3 studies
(16, 33, 49) that only used BW as inclusion criterion. When these
three studies were pooled, meta-analysis showed a MD in GA
of 2.23 weeks (95% CI 1.66–2.79). Meta-analysis also found, as
expected for a condition defined primarily using BW, that infants
in the SGA group were significantly lighter at birth (18 studies,
MD−379 g, 95% CI−452 to−306, Table 1). Both meta-analyses
of GA and BW showed high statistical heterogeneity (Table 1).
We performed additional sensitivity analysis to investigate
the possible influence of the differences in GA between the
SGA/IUGR and the control group on the association between
PDA and growth restriction. Meta-analysis of studies where
infants with growth restriction were born more than 0.5
weeks later than control infants, found a protective effect of
being growth restricted against PDA (Table 2). In contrast,
meta-analysis of studies where growth-restricted infants were
born <0.5 weeks later than control infants could not find
a significant effect of growth restriction on PDA (Table 2).
Meta-regression confirmed that the difference in effect size
between these subgroups was statistically significant (p =
0.009, Supplementary Figure 3). When we grouped the
studies according to the criteria of having or not having a
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FIGURE 3 | Meta-analysis of mean difference in gestational age (GA) between growth restricted group and control. CI: confidence interval; SGA: small for gestational
age; IUGR: intrauterine growth restriction.
TABLE 1 | Meta-analyses of confounding variables.
Meta-analysis k Effect size 95% CI p Heterogeneity
I2 p
Gestational age (MD) 18 0.63 weeks 0.24 to 1.03 0.002 94% <0.001
Birth weight (MD) 18 −379g −452 to −306 <0.001 97% <0.001
Antenatal corticosteroids (OR) 17 1.18 0.94 to 1.49 0.159 59% 0.001
Respiratory distress syndrome (OR) 23 0.77 0.60 to 0.98 0.035 78% <0.001
CI: confidence interval; k: number of studies; MD: mean difference (growth restricted group minus control group); OR: odds ratio.
statistically significant difference (p < 0.05) in GA between
the SGA/IUGR and the control group, we found similarly
that growth restriction was only a protective factor for PDA
when growth-restricted infants were born significantly later
than control infants (Table 2), and this difference between
subgroups was also confirmed through meta-regression (p =
0.008, Supplementary Figure 4). In addition, meta-regression
showed a significant linear correlation between MD in GA and
risk of PDA (Figure 4). Sensitivity analysis of studies which only
included infants with a GA <28 weeks or a <1,000 g BW found
a significant association between SGA/IUGR and PDA (Table 2,
Supplementary Figure 5).
In another subgroup analysis, we tested whether
the studies that screened all infants for PDA (see
Supplementary Table 1) showed a different effect size for
the association between SGA/IUGR and PDA. As shown in
Table 2 and Supplementary Figure 6, universal screening for
PDA did not significantly affect the OR of the association
between SGA/IUGR and PDA (meta-regression p = 0.990).
Finally, we performed additional meta-analyses to investigate
whether the rate of use of ACS and the rate of RDS were different
in the SGA/IUGR and the control group. As shown in Table 1,
rate of ACS use was not significantly different but RDS rate
was significantly reduced in the SGA/IUGR group. However,
the significant negative association between SGA/IUGR and
RDS was only observed for the subgroup of studies using the
10th percentile definition of SGA (OR 0.70, 95% CI 0.51–
0.95). Meta-regression could not demonstrate a significant
correlation between the effect size of the association between
SGA/IUGR and PDA and the effect size of the association
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TABLE 2 | Subgroup analyses.
Subgroup criteria k OR 95% CI p Heterogeneity
I2 p
SGA/IUGR-group had a MD in GA <0.5 weeks compared to control 10 1.19 0.82–1.71 0.357 57% 0.014
SGA/IUGR-group had a MD in GA ≥0.5 weeks compared to control 8 0.60 0.41–0.89 0.010 16% 0.303
SGA/IUGR-group did not differ significantly in GA from control (p ≥ 0.05) 11 1.15 0.81–1.63 0.432 52% 0.022
SGA/IUGR-group did differ significantly in GA from control (p < 0.05) 7 0.58 0.38–0.87 0.009 24% 0.244
All infants had GA ≤28 weeks or BW ≤1,000 g 28 0.81 0.67–0.97 0.020 55% <0.001
All infants were screened for PDA 16 0.72 0.53–0.97 0.031 53% 0.007
Presence of PDA was assessed in selected infants 7 0.68 0.54–0.87 0.002 55% 0.036
k: number of studies; OR: odds ratio; CI: confidence interval; SGA: small for gestational age; IUGR: intrauterine growth restriction; GA: gestational age; MD: mean difference; BW: birth
weight; PDA: patent ductus arteriosus.
FIGURE 4 | Meta-regression of mean difference in gestational age (GA) between growth restricted and control groups and risk of developing patent ductus arteriosus
(PDA). CI: confidence interval.
between SGA/IUGR and RDS (p = 0.287, R2 analog: 0.13,
Supplementary Figure 7).
DISCUSSION
Meta-analysis of observational studies presents challenging
methodological issues involving differences in the design of the
studies (i.e., cohort and case-control), assessment of exposure
and outcomes, and control for potential confounders (24, 71–73).
One of the main difficulties in understanding the relationship
between IUGR and PDA is the lack of agreement among
clinicians and investigators as to what defines these two clinical
entities. In the present meta-analysis, we observed a significantly
reduced rate of PDA in the SGA/IUGR group when all the
studies were pooled. However, analysis of the subgroups with
a more refined definition of either growth restriction or PDA
could not confirm the association between the two conditions.
In addition, we detected that some studies may be biased by
including infants with lower GA in the control group.
Very recently, using the Delphi procedure, a consensus
definition of neonatal growth restriction was reached by an
international panel of pediatric leaders in the field (10). It was
proposed to use the term “growth restriction in the newborn”
to differentiate neonatal growth restriction from fetal growth
restriction and SGA because, despite the overlapping among
these terms, infants defined by them are not the same (10). The
consensus proposed that the “use of a unique term will promote
clarity in the categorization of infants, both in clinical practice
and research, and will prevent conflation and confusion with
SGA” (10). Growth restriction in the newborn was defined by a
BW below the 3rd percentile on population-based or customized
growth charts or at least 3 out of 5 of the following: BW <10th
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percentile; head circumference <10th percentile; length <10th
percentile; prenatal diagnosis of FGR; and maternal pregnancy
information (e.g., hypertension or preeclampsia) (10). Therefore,
a BW below the 10th percentile is not considered sufficient to
define neonatal growth restriction (10). Interestingly, meta-
analyses of the studies in which SGA was based on BW below
the 10th percentile or percentile was not clearly specified were
the only analyses showing a significant reduced risk of PDA in
the SGA infants. In contrast, we did not observe a significant
association between neonatal growth restriction and PDA when
the studies using the 3rd percentile criteria and/or prenatal
diagnosis of FGR were pooled. Therefore, when the growth
restriction definition was refined, the negative association
between growth restriction and PDA was not further observed.
Most studies included in the present meta-analysis used
population-based BW references to define SGA infants. These
references have been developed with large databases and provide
BW percentiles by each GA (74–76). However, BW may not
represent intrauterine growth trajectory at a given GA because
preterm infants are more likely to be growth-restricted. Thus,
the 10th or the 3rd percentile of the BW reference in very
preterm infants are substantially lower than the corresponding
percentiles of the ultrasound-based fetal weight reference (75).
Consequently, it has been suggested that, when compared
to ultrasound-based fetal weight references, population BW
references significantly under-diagnose growth restricted infants
in very preterm births (74–76). Alternatively, prescriptive and
customized BW references have been proposed to improve the
detection of growth restricted infants at higher risk of neonatal
mortality and morbidity (10, 76). Prescriptive BW references
are derived from infants who were not exposed to antenatal
risk factors of FGR (76), whereas customized growth charts are
population-based growth charts that have been adjusted for
factors predicting BW such as maternal height and weight or
ethnic group (10).
Besides the definition of the exposure (i.e., growth restriction),
the definition of the outcome (i.e., PDA) is also controversial.
Clear evidence is lacking for or against many of the current
approaches to a PDA in very preterm infants. These uncertainties
have resulted in different definitions of what is considered
a “significant PDA” as well as in treatment strategies, which
range from aggressive management to a more conservative
approach, with some suggesting that the PDA is an innocent
bystander to adverse outcomes (2, 3, 77–80). In 27 of the
47 included studies, PDA was defined as hemodynamically
significant and/or PDA requiring treatment. When these 27
studies with a more refined PDA definition were pooled,
meta-analysis could not show an association between significant
PDA and neonatal growth restriction. In addition, we detected
considerable heterogeneity concerning the time of and the
indication for PDA assessment. Studies including only selected
patients at high risk for PDA or with clinical findings suggestive
of the condition may have different rates of PDA than studies
screening all very or extremely preterm infants. However,
subgroup analysis and meta-regression could not demonstrate
that the OR for the association between SGA/IUGR and PDA
is different between the studies with or without universal PDA
screening. Unfortunately, the marked heterogeneity of the
time of assessment of PDA did not allow us to perform any
meaningful subgroup analysis on timing.
Failure to account for significant differences in baseline
characteristics between groups in observational studies can
lead to biased estimates. The major risk factor for PDA is low
GA (1–4). We detected that in a substantial number of the
included studies the SGA/IUGR group had a higher GA than
the control group (see Figure 3). The difference in GA was
particularly marked in the studies using BW, but not GA, as
inclusion criterion. These facts may contribute to explain the
“protective” effect of growth restriction on PDA development.
Meta-regression analysis confirmed the correlation between the
difference in GA between the SGA/IUGR and the control group
and PDA risk. Moreover, subgroup analyses limited to studies
without substantial difference in GA between the SGA and the
control group could not find a significant association between
SGA/IUGR and PDA. Zeitlin et al. assessed the prevalence of
SGA age among 7,766 very preterm infants (GA below 32 weeks)
from 11 European countries and observed that this prevalence
was lower when GAwas under 28 weeks (81). They speculate that
this difference may reflect fewer indicated deliveries for growth
restriction among extremely preterm infants (81). Etiology of
very preterm birth (i.e., GA <32 weeks) can be divided into
two main categories: infection/inflammation and dysfunctional
placentation (82). However, the distribution of these two
etiologies is not homogeneous. Infants with dysfunctional
placentation are frequently less preterm and this etiology is
strongly associated with growth restriction (82). In addition, very
early mortality, which is a competing outcome for PDA, is also
more frequent in the more preterm infants. Altogether this may
explain the higher presence of older infants in the SGA/IUGR
group. Nevertheless, when we performed a subgroup analysis
that only included extremely preterm infants (GA <28 weeks),
the results did not substantially differ from the meta-analysis
including all preterm infants (Table 2, Supplementary Figure 5).
A common classical assumption among neonatologists
is that the intrauterine stress associated with IUGR would
accelerate lung maturation leading to a reduced rate of RDS
(6). However, the evidence supporting this idea is scarce and, as
reviewed by Rosenberg (6), even a number of studies reported
a significantly increased risk of RDS in very preterm infants
with IUGR. The relationship between PDA and RDS in very
preterm infants is complex and bidirectional. In many instances,
the presence of a hemodynamically significant PDA is suspected
only on the basis of respiratory findings, such as increasing
requirements for supplemental oxygen or mechanical ventilation
(83). Conversely, changes in pulmonary precapillary tone as
consequence of RDS evolution and/or therapy can alter the
left-to-right PDA shunt (83). Therefore, we aimed to analyze
the possible role of RDS on the association between PDA and
neonatal growth restriction. Twenty-three studies included in
our review reported on RDS rate and, when pooled, we observed
that the protective effect against RDS was only present in the
subgroup of studies using the definition of SGA based on BW
below the 10th percentile. In addition, meta-regression could
not demonstrate a significant correlation between the effect
size of the association SGA/PDA and the effect size of the
association RDS/PDA.
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Besides the issue of the heterogeneity of definitions
discussed above, our study has other limitations which deserve
consideration. Only 3 studies examined growth restriction
and PDA as their primary objective (13, 32, 69). Moreover,
many cohort studies did not describe the role of GA or
other confounders in infants with and without IUGR/SGA,
which makes distinguishing the effect of IUGR from that of
confounding factors difficult. Finally, for some definitions of
SGA/IUGR only a limited number of studies could be included
in subgroup analysis. The strengths of our study also deserve
mention, including a comprehensive search, a large number
of included studies, inclusion and data extraction by several
researchers to reduce bias, and analysis of confounders through
subgroup analyses and meta-regression.
CONCLUSION
The present systematic review and meta-analysis could not
provide conclusive evidence on the association between
neonatal growth restriction and PDA risk because of marked
heterogeneity in definitions of both the insult and the outcome
(i.e., significant PDA) as well as group differences in relevant
baseline characteristics, such as GA, across the studies. An
improved understanding of factors influencing the natural
history of PDA and the risk factors for the condition may
promote enhanced precision regarding diagnosis, monitoring,
and treatment selection. Further investigation is needed to
analyze whether specific conditions leading to neonatal growth
retardation such as preeclampsia or pregnancy hypertensive
disorders are associated with an altered risk of developing PDA
or other complications in very preterm infants.
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